E Fund Management Co. Ltd. Purchases New Shares in Bristol Myers Squibb Company $BMY

E Fund Management Co. Ltd. acquired a new position in shares of Bristol Myers Squibb Company (NYSE:BMY) during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund acquired 12,879 shares of the biopharmaceutical company’s stock, valued at approximately $742,000.

Several other institutional investors and hedge funds also recently made changes to their positions in BMY. waypoint wealth counsel bought a new position in Bristol Myers Squibb in the 4th quarter valued at $1,194,000. Life Cycle Investment Partners Ltd bought a new stake in shares of Bristol Myers Squibb during the 4th quarter worth $34,406,000. Lazard Asset Management LLC boosted its holdings in shares of Bristol Myers Squibb by 23.7% in the 1st quarter. Lazard Asset Management LLC now owns 1,924,036 shares of the biopharmaceutical company’s stock worth $116,693,000 after buying an additional 368,193 shares during the last quarter. Axxcess Wealth Management LLC grew its position in Bristol Myers Squibb by 27.4% during the fourth quarter. Axxcess Wealth Management LLC now owns 98,665 shares of the biopharmaceutical company’s stock valued at $5,322,000 after buying an additional 21,196 shares during the period. Finally, Asset One Wealth Management LLC purchased a new stake in Bristol Myers Squibb during the fourth quarter worth about $4,075,000. Hedge funds and other institutional investors own 76.41% of the company’s stock.

Wall Street Analyst Weigh In

BMY has been the subject of several research analyst reports. Weiss Ratings upgraded shares of Bristol Myers Squibb from a “hold (c+)” rating to a “buy (b-)” rating in a research note on Tuesday. Sanford C. Bernstein raised Bristol Myers Squibb from a “market perform” rating to an “outperform” rating in a report on Wednesday, August 5th. Royal Bank Of Canada raised their target price on Bristol Myers Squibb from $60.00 to $64.00 and gave the stock a “sector perform” rating in a research report on Friday, July 31st. Raymond James Financial began coverage on Bristol Myers Squibb in a research note on Wednesday, August 5th. They issued a “strong-buy” rating on the stock. Finally, Guggenheim reiterated a “buy” rating and set a $75.00 price target (up from $72.00) on shares of Bristol Myers Squibb in a research note on Friday, July 31st. One equities research analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating, ten have assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $66.06.

Bristol Myers Squibb Trading Up 2.3%

Shares of BMY stock opened at $67.59 on Thursday. The company has a market capitalization of $138.06 billion, a PE ratio of 14.89, a price-to-earnings-growth ratio of 0.17 and a beta of 0.22. Bristol Myers Squibb Company has a 52-week low of $42.52 and a 52-week high of $68.64. The business’s fifty day moving average is $60.18 and its 200 day moving average is $59.24. The company has a debt-to-equity ratio of 1.89, a quick ratio of 1.38 and a current ratio of 1.53.

Bristol Myers Squibb (NYSE:BMY) last announced its earnings results on Thursday, July 30th. The biopharmaceutical company reported $2.04 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.60 by $0.44. Bristol Myers Squibb had a net margin of 18.87% and a return on equity of 66.90%. The business had revenue of $12.97 billion during the quarter, compared to analyst estimates of $11.74 billion. During the same period in the previous year, the business posted $1.46 earnings per share. Bristol Myers Squibb’s revenue for the quarter was up 5.7% on a year-over-year basis. Bristol Myers Squibb has set its FY 2026 guidance at 6.750-7.000 EPS. On average, equities research analysts anticipate that Bristol Myers Squibb Company will post 6.95 EPS for the current fiscal year.

Bristol Myers Squibb Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Monday, August 3rd. Shareholders of record on Thursday, July 2nd were given a dividend of $0.63 per share. This represents a $2.52 dividend on an annualized basis and a yield of 3.7%. The ex-dividend date was Thursday, July 2nd. Bristol Myers Squibb’s dividend payout ratio (DPR) is presently 55.51%.

About Bristol Myers Squibb

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.